• NICE consults again on multiple myeloma drug

    NICE is consulting again on the use of lenalidomide (Revlimid, Celgene) for treating the blood cancer multiple myeloma after one prior treatment with bortezomib. With the further information provided by the manufacturer, the committee’s new draft guidance still does not recommend lenalidomide for this indication.

    31 July 2014

Press releases for last 7 days

Get involved